Avapritinib for treating unresectable or metastatic gastrointestinal stromal tumours (terminated appraisal) (TA730)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 29 September 2021
Capecitabine for the treatment of advanced gastric cancer (TA191)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 28 July 2010
Durvalumab in combination for neoadjuvant and adjuvant treatment of resectable gastric and gastro-oesophageal junction cancer [ID6374]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Endoscopic full thickness removal of gastrointestinal stromal tumours of the stomach (IPG717)Product type:GuidanceProgramme:Interventional procedures guidancePublished: 2 March 2022
Imatinib for the adjuvant treatment of gastrointestinal stromal tumours (TA326)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 26 November 2014
Imatinib for the treatment of unresectable and/or metastatic gastrointestinal stromal tumours (TA209)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 24 November 2010
Imatinib for the treatment of unresectable and/or metastatic gastro-intestinal stromal tumours (TA86)Product type:GuidanceProgramme:Technology appraisal guidanceLast updated: 1 November 2010Published: 27 October 2004
Laparoscopic gastrectomy for cancer (IPG269)Product type:GuidanceProgramme:Interventional procedures guidancePublished: 23 July 2008
Lenalidomide plus dexamethasone for previously untreated multiple myeloma (TA587)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 26 June 2019
Lutetium oxodotreotide with octreotide for newly diagnosed unresectable or metastatic gastroenteropancreatic neuroendocrine tumours [ID6315]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Oesophago-gastric cancer: assessment and management in adults (NG83)Product type:GuidanceProgramme:NICE guidelineLast updated: 4 July 2023Published: 24 January 2018
Pembrolizumab for previously treated endometrial, biliary, colorectal, gastric or small intestine cancer with high microsatellite instability or mismatch repair deficiency (TA914)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 20 September 2023
Pembrolizumab with lenvatinib and chemotherapy for untreated advanced gastro-oesophageal junction cancer TS ID 11861Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Ramucirumab for treating advanced gastric cancer or gastro–oesophageal junction adenocarcinoma previously treated with chemotherapy (TA378)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 27 January 2016
Regorafenib for previously treated unresectable or metastatic gastrointestinal stromal tumours (TA488)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 15 November 2017
Ripretinib for treating advanced gastrointestinal stromal tumour after 3 or more treatments (TA881)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 3 May 2023
Sunitinib for the treatment of gastrointestinal stromal tumours (TA179)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 23 September 2009
Suspected cancer (QS124)Product type:Quality standardLast updated: 5 December 2017Published: 30 June 2016
Suspected cancer: recognition and referral (NG12)Product type:GuidanceProgramme:NICE guidelineLast updated: 2 October 2023Published: 23 June 2015
Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic gastric or gastro-oesophageal junction cancer after anti-HER2 treatment (terminated appraisal) (TA879)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 6 April 2023
Trastuzumab for the treatment of HER2-positive metastatic gastric cancer (TA208)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 24 November 2010
Zolbetuximab with chemotherapy for untreated claudin 18.2-positive HER2 negative unresectable advanced gastric or gastro-oesophageal junction adenocarcinoma [ID5123]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC